iSONEP sphingomab: Completed Phase II enrollment

Lpath completed enrollment of about 158 patients in the double-blind, U.S. Phase II Nexus trial comparing monthly intravitreous injections

Read the full 193 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE